hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients-Reference-Cited by-同舟云学术

hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients

Published:2020-03 Issue:3 Volume:13 Page:100740
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Iorio Jessica,Lastraioli Elena,Tofani Lorenzo,Petroni Giulia,Antonuzzo Lorenzo,Messerini Luca,Perrone Giuseppe,Caputo Damiano,Francesconi Maria,Amato Maria Michelina,Cadei Moris,Arcangeli Giuseppina,Villanacci Vincenzo,Boni Luca,Coppola Roberto,Di Costanzo Francesco,Arcangeli Annarosa

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Systemic management of colorectal cancer;Wells;J Natl Compr Canc Netw,2017

2. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval;Sobrero;J Clin Oncol,2009

3. Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer;Wagner;Cochrane Database Syst Rev,2009

4. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer;Ferrara;Nat Rev Drug Discov,2004

5. Bevacizumab in the treatment of colorectal cancer;Mulcahy;Expert Opin Biol Ther,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?;Expert Opinion on Pharmacotherapy;2024-03-03

2. Targeting the hERG1 and β1 integrin complex for cancer treatment;Expert Opinion on Therapeutic Targets;2024-02-19

3. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer;Journal of Clinical Medicine;2023-12-21

4. Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma;Cancers;2023-03-28

5. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer;International Journal of Molecular Sciences;2023-03-19